Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 9/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24490440 | 0.99 | PDK2 (0.39) | PDK2POLBHTR7HTR2B | |
| SCHEMBL18123001 | 0.93 | PDK2 (0.37) | PDK2POLBHTR7HTR2BALDH1A1 | |
| SCHEMBL18122990 | 0.92 | PDK2 (0.37) | PDK2POLBHTR7HTR2B | |
| SCHEMBL22355421 | 0.91 | PDK2 (0.36) | PDK2POLBHTR7HTR2BALDH1A1 | |
| SCHEMBL24490489 | 0.91 | POLB (0.37) | PDK2POLBALDH1A1 | |
| SCHEMBL24490437 | 0.90 | PDK2 (0.36) | PDK2POLBHTR7HTR2B | |
| SCHEMBL24490439 | 0.90 | PDK2 (0.37) | PDK2ALDH1A1KMT2A | |
| SCHEMBL18123035 | 0.88 | PDK2 (0.41) | PDK2 | |
| SCHEMBL24490500 | 0.87 | PDK2 (0.40) | PDK2POLBHTR7HTR2BALDH1A1 | |
| SCHEMBL18926236 | 0.86 | PDK2 (0.38) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| WO-2023058418-A1 | COMPOSITION, AND PHOTOSENSITIVE COMPOSITION | 東京応化工業株式会社 | 2023-04-13 | — | — | WO | disclosed |
| US-20230002520-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| WO-2022181562-A1 | PHOTOCURABLE LIQUID COMPOSITION, CURED OBJECT, AND METHOD FOR PRODUCING CURED OBJECT | 東京応化工業株式会社 | 2022-09-01 | — | — | WO | disclosed |
| US-20220177625-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220177673-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220177641-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177625-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | CROCC, RCSD1, CRYZ | PDK2 4077/4885POLB 1371/4885HTR7 928/4885 |
| US-20220177641-A1 | CURABLE COMPOSITION, CURED PRODUCT, AND COMPOUND | CROCC, RCSD1, WDR5 | PDK2 4363/4885POLB 1946/4885HTR7 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.